Drug Trial Radar · NCT02165826
Evaluation of Tolerability and Pharmacokinetics of Roflumilast, 250μg and 500μg, as add-on to Standard COPD Treatment to Treat Severe COPD
Last checked: Nov 19, 2026Latest source record: Apr 20, 2017 (this record)Source: ClinicalTrials.govMethods & limitations
Status
Completed
Enrollment
1,323
Actual
Start
May 1, 2014
Primary completion
Sep 1, 2015
Study completion Sep 1, 2015
Sponsor
- Lead sponsor
- AstraZenecaAstraZeneca (AZN)
- Sponsor type
- Industry
- First posted
- Jun 18, 2014
Design
- Study type
- Interventional
- Phase
- Phase 3
- Allocation
- Randomized
- Model
- Parallel
- Masking
- Quadruple (participant, care provider, investigator, outcomes assessor)
- Primary purpose
- Treatment
- Who can join
- All sexes, from 40 years
- Healthy volunteers
- No
Summary
As written by the sponsor on the registry.
The purpose of this study is to evaluate discontinuation rates of roflumilast using an up-titration regimen for the first 4 weeks of treatment compared with continuous treatment of 500 μg one daily (OD) during the entire 12-week main period, and to evaluate if participants who do not tolerate roflumilast 500 μg OD have a drug exposure with 250 μg roflumilast OD similar to that observed in other participants with the 500 μg OD dose.
Conditions
- Chronic Obstructive Pulmonary Disease (COPD)
Interventions
RoflumilastDrug
Roflumilast tablets
Roflumilast PlaceboDrug
Roflumilast placebo-matching tablets
Standard of Care COPD TreatmentDrug
The participant is on standard of care COPD maintenance treatment including LABAs, long-acting anticholinergics, or any combination thereof taken on a constant daily dose within 12 weeks prior to Screening (Visit V0) Examples of LABA containing products are: Formoterol, Salmeterol, Indacaterol, Formoterol/Budesonide, Salmeterol/Fluticasone, Treatment including lon-acting anticholinergics: Tiotropium, Aclidinium.
Primary outcomes
What the sponsor says the trial is designed to measure.
- Percentage of Participants Prematurely Discontinuing Study Treatment Due to Any ReasonTime frame: Baseline to Week 12 (Main Period)
Locations
2 sites in 1 country. Site status is shown where the registry gives one.
Site not named
Bardejov, Slovakia
Site not named
Spišská Nová Ves, Slovakia
Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.